Business Wire

Neustar: DDoS Attacks Increase 180% in 2019 Compared To 2018

Share

Neustar, Inc., a global information services and technology company and leader in identity resolution, announced that its Security Operations Center (SOC) saw a 168% increase in distributed denial-of-service (DDoS) attacks in Q4 2019, compared with Q4 2018, and a 180% increase overall in 2019 vs. 2018. According to Neustar’s latest cyber threats and trends report, released today, the company saw DDoS attacks across all size categories increase in 2019, with attacks sized 5 Gbps and below seeing the largest growth. These small-scale attacks made up more than three quarters of all attacks the company mitigated on behalf of its customers in 2019.

DDoS attacks taking varied forms
In 2019, the largest threat Neustar mitigated, at 587 gigabits per second (Gbps), was 31% larger than the largest attack of 2018, while the maximum attack intensity observed in 2019, 343 million packets per second (Mpps), was 252% higher than that of the most intense attack seen in 2018. However, despite these higher peaks, the average attack size (12 Gbps) and intensity (3 Mpps) remained consistent year over year. The longest single, uninterrupted attack experienced in 2019 lasted three days, 13 hours and eight minutes.

Though the number of attacks increased significantly across all size categories, small-scale attacks (5 Gbps and below) again saw the largest growth in 2019, continuing the trend from the previous year. The combination of DDoS-for-hire and botnet rental services has made DDoS attacks much easier to execute, but the fact that perpetrators seem to be in many cases choosing to engage in small-scale attacks suggests that their goal may often be something other than taking a site completely offline.

“Large, headline-making DDoS attacks do still take place, but many cybersecurity professionals believe that smaller attacks are being used simply to degrade site performance or as a smokescreen for other forms of cybercrime, such as data theft or network infiltration, which the perpetrator can execute more easily while the target’s security team is busy fighting a DDoS attack,” said Rodney Joffe, senior vice president, senior technologist and fellow at Neustar. “Furthermore, with the current move of the bulk of the workforce globally to a work from home model, we expect to see a significant increase in DDoS attacks against VPN infrastructure. This risk makes an ‘always on’ DDoS mitigation service even more critical.”

In addition to conventional DDoS attacks, which seek to exhaust bandwidth, in 2019 Neustar also observed an increase in network protocol or state exhaustion attacks, which target network infrastructure directly. Volumetric attacks continued to proliferate as well, with attackers using new DDoS vectors such as Apple Remote Management Services, Web Services Dynamic Discovery, Ubiquiti Discovery Protocol and the Constrained Application Protocol.

Said Joffe, “During the shift to teleworking at scale, we would not be surprised to see the VPN protocol ports added to these targeted attacks.”

Two- and three-vector attacks ‘just right’ for attackers
In 2019, approximately 85% of all attacks used two or more threat vectors. That number is comparable to the 2018 figure; however, the number of attacks involving two or three vectors rose from 55% to 70%, with correspondingly fewer simple single-vector attacks and complex four- and five-vector attacks, suggesting that attackers have settled into the Goldilocks zone for attacks.

Security professionals continue to view DDoS attacks as a growing threat. According to the most recent Neustar International Security Council (NISC) survey, when asked which vectors they perceived to be increasing threats during November and December 2019, senior-level cybersecurity decision-makers cited social engineering via email most frequently (59%), followed by DDoS (58%) and ransomware (56%).

Web attacks increasing
2019 saw web attacks on the rise as well. Most companies recognise the danger that slow-loading websites pose to their business and attempt to protect them with web application firewalls. In the most recent NISC survey, 98% of respondents agreed that a WAF was an essential component of their security infrastructure. However, as more and more enterprises use multiple cloud providers, often involving a mix of public and private clouds, the need for consistent security across applications and platforms is growing.

“Web attacks can be difficult to track because some variation in the performance of websites is to be expected, but they are increasingly critical for businesses to address. One survey found 45% of consumers are less likely to make a purchase when they experience a slow loading website, and 37% are less likely to return to a retailer if they experience slow loading pages,” added Joffe.

A vendor-neutral cloud WAF, coupled with DDoS protection, can eliminate a large portion of threats, allowing enterprise application experts to focus their attention on the more specialised attacks. Continuous updates from a reliable threat feed can also deliver information on bad IPs and botnet command and control (C&C) sites before they are able to damage the network.

A complimentary copy of the Neustar 2019: The Year in Review cyber threats and trends report is available here.

-ENDS-

About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, Security and Registry that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar.

# # #

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jenny Morris
Hotwire for Neustar
+44 (0)7393465529
neustaruk@hotwireglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye